Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Times Interest Earned (2016 - 2025)

Zevra Therapeutics' Times Interest Earned history spans 11 years, with the latest figure at $4.78 for Q4 2025.

  • For Q4 2025, Times Interest Earned rose 168.05% year-over-year to $4.78; the TTM value through Dec 2025 reached -$7.89, up 33.33%, while the annual FY2025 figure was -$7.89, 33.33% up from the prior year.
  • Times Interest Earned reached $4.78 in Q4 2025 per ZVRA's latest filing, up from $2.02 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of $364.56 in Q2 2021 to a low of -$568.4 in Q4 2021.
  • Average Times Interest Earned over 5 years is -$66.21, with a median of -$23.67 recorded in 2023.
  • The largest YoY upside for Times Interest Earned was 16729.21% in 2021 against a maximum downside of 35406.82% in 2021.
  • A 5-year view of Times Interest Earned shows it stood at -$568.4 in 2021, then surged by 95.2% to -$27.29 in 2022, then rose by 26.53% to -$20.05 in 2023, then skyrocketed by 64.95% to -$7.03 in 2024, then soared by 168.05% to $4.78 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Times Interest Earned are $4.78 (Q4 2025), $2.02 (Q3 2025), and -$35.36 (Q2 2025).